Literature DB >> 8813337

Molecular genetics of antithrombin deficiency.

D A Lane1, G Kunz, R J Olds, S L Thein.   

Abstract

Antithrombin is the major proteinase inhibitor of thrombin and other blood coagulation proteinases. Antithrombin has two functional domains, a heparin binding site and a reactive centre (that complexes and inactivates the proteinase). Its deficiency results in an increased risk of venous thromboembolism. Appreciable progress has been made in recent years in understanding the structure and function of this protein, the genetic cause of inherited deficiency and its clinical consequence. The structure of antithrombin is now considered in terms of the models derived from X-ray crystallography, which have provided explanations for the function of its heparin interaction site and of its reactive loop. The structural organization of the antithrombin gene has been defined and numerous mutations have been identified that are responsible for antithrombin deficiency: these may reduce the level of the protein (Type I deficiency), alter the function of the protein (Type II deficiency, altering heparin binding or reactive sites), or even have multiple or 'pleiotropic effects' (Type II deficiency, altering both functional domains and the level of protein).

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8813337     DOI: 10.1016/s0268-960x(96)90034-x

Source DB:  PubMed          Journal:  Blood Rev        ISSN: 0268-960X            Impact factor:   8.250


  11 in total

Review 1.  Inherited risk factors for venous thromboembolism.

Authors:  Ida Martinelli; Valerio De Stefano; Pier M Mannucci
Journal:  Nat Rev Cardiol       Date:  2014-01-14       Impact factor: 32.419

2.  Causative genetic mutations for antithrombin deficiency and their clinical background among Japanese patients.

Authors:  Akiko Sekiya; Fumina Taniguchi; Daisuke Yamaguchi; Sayaka Kamijima; Shonosuke Kaneko; Shiori Katsu; Miho Hanamura; Mao Takata; Haruka Nakano; Hidesaku Asakura; Shigeki Ohtake; Eriko Morishita
Journal:  Int J Hematol       Date:  2016-11-17       Impact factor: 2.490

Review 3.  Criteria for evaluating evidence that laboratory abnormalities are associated with the development of venous thromboembolism.

Authors:  S M Bates; J S Ginsberg; S E Straus; H Rekers; D L Sackett
Journal:  CMAJ       Date:  2000-10-17       Impact factor: 8.262

4.  Complete antithrombin deficiency in mice results in embryonic lethality.

Authors:  K Ishiguro; T Kojima; K Kadomatsu; Y Nakayama; A Takagi; M Suzuki; N Takeda; M Ito; K Yamamoto; T Matsushita; K Kusugami; T Muramatsu; H Saito
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

5.  Two case reports of inherited antithrombin deficiency: a novel frameshift mutation and a large deletion including all seven exons detected using two methods.

Authors:  Akiko Sekiya; Eriko Morishita; Megumi Karato; Keiko Maruyama; Itsumi Shimogawara; Mika Omote; Yoshiyuki Wakugawa; Moeko Shinohara; Tomoe Hayashi; Yasuko Kadohira; Hidesaku Asakura; Shinji Nakao; Shigeki Ohtake
Journal:  Int J Hematol       Date:  2011-01-18       Impact factor: 2.490

6.  Vascular dermatan sulfate regulates the antithrombotic activity of heparin cofactor II.

Authors:  Li He; Tusar K Giri; Cristina P Vicente; Douglas M Tollefsen
Journal:  Blood       Date:  2008-02-15       Impact factor: 22.113

Review 7.  Heparan sulfate 3-O-sulfation: a rare modification in search of a function.

Authors:  Bryan E Thacker; Ding Xu; Roger Lawrence; Jeffrey D Esko
Journal:  Matrix Biol       Date:  2013-12-19       Impact factor: 11.583

8.  Five novel and four recurrent point mutations in the antithrombin gene causing venous thrombosis.

Authors:  Keiko Nagaizumi; Hiroshi Inaba; Kagehiro Amano; Midori Suzuki; Morio Arai; Katsuyuki Fukutake
Journal:  Int J Hematol       Date:  2003-07       Impact factor: 2.490

9.  Gene analysis of inherited antithrombin deficiency and functional analysis of abnormal antithrombin protein (N87D).

Authors:  Sayaka Kamijima; Akiko Sekiya; Mao Takata; Haruka Nakano; Morika Murakami; Tomonori Nakazato; Hidesaku Asakura; Eriko Morishita
Journal:  Int J Hematol       Date:  2017-10-25       Impact factor: 2.490

Review 10.  Hereditary and acquired antithrombin deficiency: epidemiology, pathogenesis and treatment options.

Authors:  Peter S Maclean; R Campbell Tait
Journal:  Drugs       Date:  2007       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.